DMRA

Damora Therapeutics Stock Analysis

AI Rating

Good
  • Quality0/10
  • Growth↑ 5/10
  • Value↑ 8/10
Damora Therapeutics sales and earnings growth
DMRA Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 121.48%
  • FCF Y/Y↑ 63.88%
Damora Therapeutics gross and profit margin trends
DMRA Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↑ 2.84%
Damora Therapeutics net debt vs free cash flow
DMRA Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Damora Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks